- 4D Pharma (DDDD.l) (FRPRF) is an under covered UK domiciled company working in the microbiome space. The company will be NASDAQ listed in Q1 of 2021.
- 4D Pharma seeks to understand the functions of bacteria in order to harness these functions to treat disease.
- 4D Pharma has produced compelling data in immuno-oncology using their live biotherapeutic MRx0518.
- The company has a large but early stage pipeline that is progressing into the clinic. 4D Pharma appears undervalued relative to the quality of the clinical data produced in immuno-oncology and the opportunities for other products.
- There will be multiple readouts in 2021 and positive data can propel the share price upward to market caps more similar to peer companies.
For further details see:
4D Pharma: Impressive Immuno-Oncology Data